Monoclonal antibody · Antagonist of VEGFR2 (vascular endothelial growth factor receptor 2) (KDR) · developed by Eli Lilly And Co
Ramucirumab is a human monoclonal antibody that specifically binds VEGFR2 and blocks binding of the ligands VEGF-A, VEGF-C and VEGF-D, inhibiting ligand-stimulated VEGFR2 activation and endothelial cell proliferation and migration. It is used in the treatment of gastric or gastro-esophageal junction adenocarcinoma, non-small cell lung cancer, colorectal cancer and hepatocellular carcinoma.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 9, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05002127 | Phase 2/3 | Gastric Cancer | Completed | LLY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Gastric AdenocarcinomaGastric CancerGastroesophageal Junction Adenocarcinoma
Updated Nov 8, 2026. Something wrong or missing? Report it on the LLY page.
See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LLY catalysts and pipeline →